VEGFA and neuromyelitis optica: Clinical trials targeting VEGF in autoimmune diseases are already ongoing, e.g., the VEGF inhibitor bevacizumab (Avastin®) has been administered as an add-on therapy to high doses of corticosteroids for the treatment of acute optic neuritis and/or transverse myelitis in neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD) (NCT01777412).